Laboratory Corp. of America Holdings (LH) Shares Sold by KBC Group NV

KBC Group NV decreased its holdings in Laboratory Corp. of America Holdings (NYSE:LH) by 37.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,913 shares of the medical research company’s stock after selling 35,862 shares during the period. KBC Group NV owned about 0.06% of Laboratory Corp. of America worth $9,716,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in LH. Boston Partners increased its stake in shares of Laboratory Corp. of America by 13.9% during the fourth quarter. Boston Partners now owns 5,264,025 shares of the medical research company’s stock worth $839,665,000 after purchasing an additional 644,355 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Laboratory Corp. of America by 57.4% during the third quarter. JPMorgan Chase & Co. now owns 1,350,903 shares of the medical research company’s stock worth $202,298,000 after purchasing an additional 492,866 shares during the period. Check Capital Management Inc. CA increased its stake in shares of Laboratory Corp. of America by 95.2% during the third quarter. Check Capital Management Inc. CA now owns 526,500 shares of the medical research company’s stock worth $79,486,000 after purchasing an additional 256,802 shares during the period. Canada Pension Plan Investment Board increased its stake in shares of Laboratory Corp. of America by 1,250.0% during the third quarter. Canada Pension Plan Investment Board now owns 238,788 shares of the medical research company’s stock worth $36,050,000 after purchasing an additional 221,100 shares during the period. Finally, PGGM Investments increased its stake in shares of Laboratory Corp. of America by 254.1% during the fourth quarter. PGGM Investments now owns 293,200 shares of the medical research company’s stock worth $46,768,000 after purchasing an additional 210,408 shares during the period. Hedge funds and other institutional investors own 91.70% of the company’s stock.

A number of brokerages have recently weighed in on LH. Zacks Investment Research upgraded Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. ValuEngine lowered Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Craig Hallum reiterated a “buy” rating and set a $204.00 target price (up previously from $180.00) on shares of Laboratory Corp. of America in a research note on Wednesday, February 7th. Evercore ISI began coverage on Laboratory Corp. of America in a research note on Thursday, January 4th. They set an “outperform” rating and a $176.00 target price on the stock. Finally, Barclays increased their target price on Laboratory Corp. of America from $183.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, October 26th. Six research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $180.73.

In other Laboratory Corp. of America news, Director Adam H. Schechter sold 1,263 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $169.29, for a total value of $213,813.27. Following the sale, the director now owns 7,297 shares of the company’s stock, valued at approximately $1,235,309.13. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Glenn A. Eisenberg sold 8,400 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $167.36, for a total value of $1,405,824.00. Following the completion of the sale, the chief financial officer now directly owns 15,931 shares in the company, valued at approximately $2,666,212.16. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

Laboratory Corp. of America Holdings (LH) opened at $172.69 on Thursday. Laboratory Corp. of America Holdings has a 52 week low of $134.10 and a 52 week high of $181.71. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.20 and a current ratio of 1.31. The company has a market capitalization of $17,408.82, a price-to-earnings ratio of 17.81, a price-to-earnings-growth ratio of 1.50 and a beta of 0.93.

Laboratory Corp. of America (NYSE:LH) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, topping the Zacks’ consensus estimate of $2.38 by $0.07. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The firm had revenue of $2.70 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same quarter last year, the company earned $2.15 EPS. The company’s revenue was up 13.2% on a year-over-year basis. equities analysts forecast that Laboratory Corp. of America Holdings will post 11.52 earnings per share for the current year.

WARNING: “Laboratory Corp. of America Holdings (LH) Shares Sold by KBC Group NV” was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://weekherald.com/2018/02/15/laboratory-corp-of-america-holdings-lh-shares-sold-by-kbc-group-nv.html.

Laboratory Corp. of America Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply